Ergebnisse der 1. Österreichischen Ovarialkarzinom-Studie: Prospektiv randomisierter Vergleich einer neuen sequentiellen Chemotherapie mit 2 Standard-Schemata bei 150 Patientinnen des Stadiums III und IV

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Dargestellt werden die Ergebnisse einer randomisierten Studie bei 150 Patientinnen, die entweder mit 6 Zyklen Adriamycin (40 mg/m2) und Cyclophosphamid (500 mg/m2) behandelt wurden oder einer Kombination aus Adriamycin (40 mg/m2) und Cis-Platin (50 mg/m2) oder einer Kombination im Rahmen eines Wechselschemas: Adriamycin (40 mg/m2, Tag 1), Cis-Platin (100 mg/m2, Tag 2), Vincristin (1,4 mg/ m2, Tag 28), Cyclophosphamid (1500 mg/m2, Tag 25), Methotrexat (1000 mg, Tag 56) (insgesamt zwei Zyklen). Die mittleren Überlebenszeiten waren am längsten beim Wechselschema (19,6 Monate). Am deutlichsten profitierten die Patienten mit hochdifferenzierten Tumoren von dieser Art von Chemotherapie: mittlere Überlebenszeit 26,3 Monate gegenüber 17,6 Monaten.

Related collections

Author and article information

Journal

Journal ID (publisher-id): ONK

Journal ID (nlm-ta): Oncol Res Treat

Journal ID (doi): 10.1159/issn.2296-5270

Title: Oncology Research and Treatment

Publisher: S. Karger AG

ISSN (Print): 2296-5270

ISSN (Electronic): 2296-5262

Publication date Subscription-year: 1985

Publication date (Print): 1985

Publication date (Electronic): 24 April 2009

Volume: 8

Issue: 6

Pages: 388-391

Affiliations

^aI. Univ.-Frauenklinik Wien (Vorstand: Prof. Dr. E. Gitsch)

Article

Publisher ID: 215693 Other ID: Onkologie 1985;8:388–391

DOI: 10.1159/000215693

PubMed ID: 3912695

SO-VID: 52b095c7-5410-45f6-a5e9-92b7215aa076

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Call for Papers: Beyond Biology: The Crucial Role of Sex and Gender in Oncology

Submit here before May 31, 2024

Ergebnisse der 1. Österreichischen Ovarialkarzinom-Studie: Prospektiv randomisierter Vergleich einer neuen sequentiellen Chemotherapie mit 2 Standard-Schemata bei 150 Patientinnen des Stadiums III und IV

Read this article at

Abstract

Related collections

Karger: Oncology

Author and article information

Journal

Affiliations

Article

History

Page count

Categories

Comments

Comment on this article

Similar content 90